Mycophenolate mofetil vs Enteric-coated mycophenolate sodium in de-novo kidney transplant recipients (summary of the side effects within first three months): single center experience Micofenolato mofetilo vs Micofenolato de sodio con cubierta entérica en receptores de trasplante renal de novo (resumen de efectos secundarios en los primeros 3 meses): experiencia de un solo centro

Creative Commons License

Sözen M. H., Dalgıç A., Kozan R., Anadol A. Z.

Revista de Nefrologia, Dialisis y Trasplante, cilt.44, sa.3, ss.127-132, 2024 (SCI-Expanded) identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 44 Sayı: 3
  • Basım Tarihi: 2024
  • Dergi Adı: Revista de Nefrologia, Dialisis y Trasplante
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, Fuente Academica Plus, Directory of Open Access Journals, DIALNET
  • Sayfa Sayıları: ss.127-132
  • Anahtar Kelimeler: enteric-coated mycophenolate sodium, immunosuppression, kidney transplantation, mycophenolate mofetil, side effects
  • Gazi Üniversitesi Adresli: Evet

Özet

Aim: This study assesses and compares GI, bone marrow (BM), and hepatotoxicity side effects of MMF and EC-MPS in the first 3 months after de-novo kidney transplantation. Material and Methods: Retrospective data from 100 kidney transplant recipients were analyzed between January 2016 and December 2021 at Gazi University Transplantation Center. Patients were divided into two groups: MMF (group A, n=68) and EC-MPS (group B, n=32). Side effects within the first three months post-transplantation were assessed, including gastrointestinal side effects (dyspepsia, bloating, diarrhea), bone marrow complications, and hepatotoxicity. Statistical analysis was performed using SPSS software. Results: In group A, we have not seen any side effects of MMF in 38% of recipients during the postoperative first three months. Sixty-two percent of recipients had the following side effects: gastrointestinal 22%, bone marrow 24%, and hepatotoxicity 16%. In group B, we have not seen any side effects of EC-MPS in 43% of recipients during the postoperative first three months. Fifty-seven percent of recipients experienced the following side effects: BM in 28%, GI in 25%, and hepatotoxicity in 4%. Management involved medication adjustments, with side effects ceasing in most cases. Conclusions: In conclusion, this study highlights the overall favorable safety profiles of MMF and EC-MPS in the early post transplant period. However, it underscores the potential advantage of EC-MPS over MMF in hepatotoxicity, with EC-MPS demonstrating a lower incidence of hepatotoxicity than MMF.